喹硫平与利培酮对精神分裂症患者临床疗效与认知功能的影响研究

Comparison of Quetiapine and Risperidone on psychotic symptoms and cognitive function in patients with schizophrenia

目的对比喹硫平与利培酮对精神分裂症患者临床疗效与认知功能的改善情况。方法将50例初诊或经典抗精神病药治疗疗效不显著或无法耐受不良反应的精神分裂症患者分为喹硫平(n=25)与利培酮(n=25)2组,进行为期3个月的治疗。治疗前后应用阳性与阴性症状量表(PANSS)、简易精神状态检查表(MMES)分别评估患者的临床疗效与认知功能。结果共39例临床稳定患者(PANSS量表≤60分或PANSS减分率≥50%)完成3个月的治疗(喹硫平组19例,利培酮组20例)。与基线比较,喹硫平与利培酮治疗3个月后MMES评分较治疗前显著提高(P<0.05),PANSS总分及各子项目得分较治疗前有显著降低(P<0.05),但2组间MMES与PANSS项目评分并无差异性。结论喹硫平与利培酮治疗精神分裂症疗效显著,均能明显改善患者的认知功能,但两者之间并无统计学差异。

Objective The objective of this study is to compare effects of quetiapine and risperidone on psychotic symptoms and cognitive function in patients with schizophrenia.MethodsFifty patients with schizophrenia,who were newly diagnosed or had either failed to demonstrate sufficient clinical improvement or to tolerate adverse drug effects, were assigned to quetiapine or risperidone treatment. The psychotic symptoms and cognitive functions were assessed by PANSS or MMES tests,respectively.ResultsThirty-nine patients completed the three-month treatment. Compared with baseline,MMES scales were markedly increased（P〈0.05）,and the PANSS scale and subscales were markedly decreased（P〈0.05）after three-month treatment. However,no significant difference was observed between quetiapine and risperidone treatments.ConclusionsQuetiapine and risperidone improved equivalently psychotic symptoms and cognitive functions in patients with schizophrenia.